Chronic migraines (CM), whose external imperceptibility can lead to stigmatization, are characterized by headaches at least 15 days each month. That means “people with chronic migraine have a migraine or headache more often than not,” notes the nonprofit American Migraine Foundation. Studies have demonstrated that migraine patients have lower quality of life and professional productivity, as well as lower socioeconomic statuses.
Part of the trouble, says Kenneth Thorpe, a former deputy assistant secretary at the U.S. Department of Health and Human Services (1993-5), is that chronic migraines tend to come with comorbidities. Roughly 40 percent of chronic migraine patients suffer from an additional four chronic conditions, says Dr. Thorpe, who recently authored the paper “Prevalence, Health Care Spending and Comorbidities Associated with Chronic Migraine Patients.”
“Having chronic migraine complicates the treatment of these other conditions, increasing the treatment costs by 34 to 46 percent for conditions like diabetes and heart disease,” says Dr. Thorpe, chair of Emory University’s health policy management program. “While chronic migraine costs $5 billion per year, patients with CM spend over $41 billion on their healthcare.”
In the paper, Dr. Thorpe recommends a holistic approach to understanding chronic migraine, or “whole-person care.” Since most CM patients have at least one other chronic condition, it’s vital to focus on treating all of patients’ conditions: “chronic migraine, but at the same time depression, diabetes, and heart disease among others,” he says. “This will require providers to ‘team’ together and work together with the patient to manage their multiple chronic conditions.”
One of the paper’s focuses is an update on CM demographics (as of 2013), including:
Asked why white, urban women suffer from chronic migraines in larger percentages, Dr. Thorpe says, “A good question for future research. Stress could certainly play a role here.”
On the medication side, the paper notes several hundred medications linked to migraine treatment, but no prescription accounted for even three percent of treatments. The most popular were topiramate (2.65 percent) and hydrocodone (2.08 percent).
Prior to this research, no work had been done to understand the ways that chronic migraine complicates the treatments of other chronic conditions, according to Dr. Thorpe. “The results are novel,” he says.
The white paper outlines the prevalence of some of the comorbidities. The most common are:
CM treatment nationwide carries enormous costs, and the paper finds that treatment costs increase significantly with the number of other chronic conditions. An estimated 4.2 million CM patients spend more than $5.2 billion a year on treatment (about $1,251 per patient). For patients with CM but no other chronic conditions, treatment averaged $800 per year; for those with four or more other conditions in addition to CM, the average annual cost per patient nearly doubled to $1,554.
When one factors in that 39 percent of CM patients have four or more other conditions as well, the economic impact of CM and comorbidities may amount to $28 billion per year to treat both the CM and the other conditions.
Future research, Dr. Thorpe says, will focus on understanding more about how and why having CM increases costs for patients with mental disorders and cardiovascular disease.
The Global Healthy Living Foundation is a 501(c)(3) non-profit organization with the mission to improve the quality of life for people living with chronic illness.